FIELD: pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutics and refers to pharmaceutical composition containing antibody and polyoxyethylene (POE) sorbitan, without polysorbate, and also method of preparing composition and method of stabilising protein-containing finished forms.
EFFECT: group of inventions provides improved stability by preventing proteins aggregation in aqueous solutions.
14 cl, 11 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS, INCLUDING ALKYLGLYCOSIDES, FOR STABILISATION OF PROTEIN-CONTAINING COMPOSITIONS | 2011 |
|
RU2575830C2 |
| HIGHLY CONCENTRATED COMPOSITIONS OF ANTIBODIES AND PROTEINS | 2004 |
|
RU2332986C2 |
| RECOMBINANT MONOCLONAL ANTIBODY TO TNF-ALPHA AQUEOUS PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2665966C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNF-α | 2017 |
|
RU2764521C2 |
| SINGLE-STRANDED CD40 RECEPTOR AGONIST PROTEINS | 2016 |
|
RU2745801C2 |
| STABLE PROTEIN PREPARATIONS CONTAINING MOLAR EXCESS OF SORBITOL | 2015 |
|
RU2689145C2 |
| METHOD OF PURIFYING APO-2 LIGAND/TRAIL VIA COLD CRYSTALLISATION | 2006 |
|
RU2435781C2 |
| COMPOSITIONS OF ANTIBODIES | 2014 |
|
RU2694055C2 |
| COMPOSITIONS OF ANTIBODIES | 2005 |
|
RU2426554C2 |
| HUMANISED ANTIBODIES WITH INCREASED STABILITY | 2015 |
|
RU2684703C2 |
